Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

NCT05748561 is registered in ClinicalTrials.gov with Asociación para Evitar la Ceguera en México as lead sponsor.

NCT NCT05748561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05748561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.
Lead sponsor
Asociación para Evitar la Ceguera en México
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 5, 2022
Completion date
April 5, 2024
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietin, methylprednisolone, toxic optic neuropathy, treatment